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1134-156 Ef fects  o f  Antidepressant Medication on Morta l i ty  in 
Patients With Congestive Heart Failure 
Grad L. Clarv. Charles Davenport, Donna Biracree, Maragatha Kuchibhatla, Dipen Shah, 
Christopher M. O'Connor, Ranga R. Krishnan, Duke University Medioa/Center, Durham, 
North Carolina. 
Major Depressive Disorder (MDD) is a common entity in patients with cardiovascular 
(CAD) disease. Studies have previously demonstrated that MDD is present in 20%-45% 
of CAD patients. Rates of depressive disorders following myocardial infarction (MI) are 
especially high, with a depressive episode in 50% of patients immediately following MI, 
and more than 70% at one year after MI. Congestive heart failure (CHF) due to ischemia 
occurs in many of these patients. Despite numerous studies in this population, few have 
focused on the prevalence of depression and its pr(xJnostic effect in patients with CHF. 
Recently Jiang st al, published results demonstrating that overall mortality in patients 
with co-morbid CHF and depression was increased at 3 months and 1 year compared to 
patients with CHF who were not depressed. MDD with CHF was found to be an indepen- 
dent risk factor for increased mortality, in the current work we have confirmed these find- 
ings, with increased mortality in patients with CHF and co-morbid depression by Beck 
Depression Inventory (BDI=10) in a group of 674 patients with ejection fraction less than 
or equal to 35%. Patients who were not depressed at baseline but had CHF had a mor- 
tality rate of 12.12%. Those patients at baseline on antidepressant medication, and in all 
likelihood responsive to medication, had a mortality rate of 14.14%, While patients who at 
baseline were depressed and treated with medication, suffered increased mortality over 
controls at 22.52%. In CHF patients with major depression whose depressive symptoms 
did not respond to medication effect had an even higher rate of mortality at 38.60% (p- 
value=0.5). This data suggests that patients with co-morbid CHF and depression and 
who remain non-responders despite medication have higher rates of mortality over those 
without depression, or those patients responsive to medication, This work proposes that 
the effect of adequately treating depression in patients with CHF may reduce mortality, 
and if the CHF/depressed patient remains non-responsive to medication, mortality may 
be significantly higher than that either depressed-responsive/CHF or non-depressed 
patients with CHF. 
1134-157 Endothelin Antagonism With Bosentan, a Dual Receptor 
Blocker, Normalizes Dyaregulatsd Transforming Growth 
Factor Bets Signaling Pathways in Rats With Chronic 
Heart Failure 
Ingeborg Schafhalter-Zoppoth, Mary O. Gray, John R. Tearlink, San Francisco VA 
Medical Center, San Francisco, California, UCSF, San Francisco, California. 
Background: We have previously shown that dysregulation of the TGF beta signaling 
pathway is correlated with adverse ventdoular remodeling in CHF. Endothelin (ET) also 
plays a central role in ventdcular remodeling and many of its actions are mediated by 
TGF beta. Therefore, we hypothesized that the beneficial effects of ET antagonism with 
bosentan on ventricular emodeling may be mediated by improvements in the TGF beta 
signaling pathway. 
Methods: Adult male Sprague-Dawley rats (270-300g) underwent coronary artery ligation 
(CAL) or sham operation (Sham group) followed by conscious echocardiography on day 
5-7 after surgery, CAL rats with ejection fraction 3 in all groups), 
Results: Baseline data (EF, body weight) showed no differences between the treatment 
groups. In myocytes from CHF rats, bosantan tended to increase inhibitory Smed6 by 
51% (p=0.13), with no effect on the positive effectors, Smad3 or Smad4. in fibroblasts 
from CHF rats, bosentan decreased Smad4 and SARA (Smad anchor for receptor acti- 
vation; p=0,018) to normal and significantly increased Smad6 (97%; p=0.026). The 
improvements in fibroblast Smad6 concentrations directly correlated with attenuation of 
ventricular dilation by bosentan, as measured by LV volume at 20 mmHg distending 
pressure (p<0.01 ; r=0.6g). 
Conclusion: These data confirm our earlier findings of TGF beta signaling pathway dys- 
regulation in CHF and demonstrate that chronic ET blockade with bosentan results in 
normalization of these pathways, Inhibition of the TGF beta pathway was directly corre- 
lated to the beneficial effects of bosentan on ventricular emodeling. These findings sug- 
gest that the TGF beta pathway may mediate the adverse effects of endothslin in CHF 
and that this pathway may be an important herapeutic target in CHF. 
1134-158 Long-Term Carved i lo l  T reatment  in Idiopathic Dilated 
Cardiomyopathy: Biological Effects Beyond 
Pharmacological Act iv i ty  
Renata De Maria. Antonello Gavazzi, Gianfranco Sinsgra, Oberdan Parodi, Carlo 
Campana, Danilo Nsglia, Mauro Ciacched, Marce)la Luvini, Luigi Lavecchia, CNR 
Clinical Physiology/nstitute, Section of Milan, Milan,/taly, Cardiovascular DpL Ospedali 
Riuniti, Bergamo, Italy. 
Background. Despite the established effects of carvedilol on morbility and mortality in 
heart failure (HF), the mechanisms of its ctinical efficacy are still poorly understood. We 
conducted a multlcenter, double-blind, randomized, placebo-controlled trial in HF 
patients with idiopathic dilated cardiomyopathy to assess the effects of carvedilol (C) on 
submaximal exercise tolerance during long-term pharmacological treatment and after 
withdrawal. Methods and Results. 99 patients with HF due to documented idiopathic 
dilated cardiomyopathy and an ejection fraction <=0.36 underwent a 2-week open-label 
challenge with C; 84 of them (mean age 54¢10 years, 64 males) were randomized to 
chronic treatment with C (n=45), titrated up to 25 mg bid (mean final dose 23.1±4.8 bid) 
or placebo (P), (n=39) on top of ACE-inhibitors and form the intention-to-treat sample. 
After 6-month treatment, Minnesota Living with Heart Failure (MLWHFQ) questionnaire, 
echo ejection fraction and submaximal exercise stress test were compared to baseline; 
exercise tolerance was again assessed after 5.4±5 days wash-out. Improvement in sub- 
maximal exercise tolerance, defined as a 20% increase and an absolute increase of at 
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least 60 sac in exercise duration after 6-month treatment vs baseline, occurred in 51% of 
C and 23% of P (p=O.01). Changes in exercise duration were 103±257 sac in C vs - 
19±160 sac in P during chronic treatment and 123±306 sac in C vs -2±178 sec in P after 
wash-out (p=0.014 for treatment effect). Peak exercise systolic blood pressure and heart 
rate did not change in both groups. MLWHFQ total score decreased by -5+12 points in C 
vs -1±9 points in P (p=O.01); MLWHFQ physical dimension score decreased by -2±5 
points in C vs 0±4 points in P (p=0.03). Ejection fraction increased by 6.1±8.9 units in C 
vs 3.2±5.2 Units in P (p=0,08). Conclusions, In idiopathic dilated cardiomyopsthy, C 
determines during long-term treatment, beyond an improvement in symptoms and sys- 
tolic function, a significant increase in submaximsl exercise tolerance, that is maintained 
even after pharmacological wash-out. The sustained effects after drug withdrawal indi- 
cate that C-inducad benefits in HF are biologically-mediated. 
1134-159 Ef fect  o f  Valeartan on Time-Adjusted and 
Hospitalization Frequency Rate in the Valsartan Heart 
Failure Trial 
Peter E. Carson, Jay N, Cohn, for the VaI-HeFT Investigators, VA Medical Center, 
Washington, Dist. of Columbia, Univereity of Minnesota, Minneapolis, Minnesota. 
Background: In the Valsartan Heart Failure Trial (VaI-HeFT), risk for time to first heart 
failure (HF) hospitalization adjudicated by the Endpoint Committee was reduced by 
27.5% with valsartan versus placebo in 5010 patients with NYHA class II-IV HF receiving 
prescribed therapy. HF and cardiovascular (CV) hospitalizations (Investigator-classified) 
were markedly reduced (HF 22.4%, CV 15,4%) by vslsartan versus placebo. Significant 
reductions were also seen in subgroups defined by background therapy (angiotensin 
converting enzyme inhibitor = ACE, beta blocker = BB), principally in patients not on BB, 
However, total hospitalization data should be adjusted for time at risk to account for dif- 
ferential mortality. 
Methods: For purposes of this analysis, cause of hospital admissions was investigator- 
classified. 
Results: In VaI-HeFT, a reduction in HF and CV hospitalization rate with valsartan is 
observed in' all subgroups except those treated with both ACE and BB. The number of 
patients hospitalized also was reduced by valsartan compared to placebo, particularly 
those hospitalized more than once (1: HF 8.7%, CV 7.5%; 2 or more: HF 20.7%, CV 
11.6%). 
Conclusion: The beneficial affects on the overall HF and CV hospitalization rates in Val- 
HeFT confirm the adjudicated first HF hospitalization sndpoint. Reduction of hospitaliza- 
tion rates is most strongly noted in patients with recurrent hospitalizations. 
HF Hospitalizations 
Total Number Per patient-year 
Subgroup Valsartan Placebo Valsartan Placebo p-value 
All 923 1189 0.30 0.36 0.001 
BB=yes 266 298 0.25 0.24 0.686 
BB=no 657 891 0.32 0.43 <0.001 
ACE=yes 872 1072 0,31 0.35 0.011 
ACE=no 51 117 0.18 0,51 0.007 
BB(y)+ACE(y) 254 269 0,27 0,22 0.953 
BB(y)+ACE(n) 12 29 0.11 0,45 0.102 
BB(n)+ACE(y) 618 803 0.33 0.42 0,002 
BB(n)+ACE(n) 39 88 0.22 0.55 0.032 
1134-160 Early Detection of Regional Myocardial Dysfunction by 
Strain Doppler Echocardlogrephy in Patients With 
Primary Amyloidosis 
Jun Kovama, Patricia A. Ray-Sequin, Giulia Russo, Rodney H. Falk, Boston Medical 
Center, Boston, Massachusetts. 
Background: Tissue Doppler imaging (TDI) shows a reduced longitudinal myocardial 
velocity gradient between the base and mid-ventricle in amyloidosis with heart failure 
(CHF). We sought to determine the precise site of the regional contractile abnormality 
using strain rate imaging (SRI). 
Methods: 88 biopsy-proven patients with AL amyloidosis underwent TDI and SRI. 54 had 
heart involvement, of whom 26 had CHE 28 had cardiac involvement but no CHF and 34 
had non-cardiac amyloid (controls). Sample volumes were placed on basal, mid, and api- 
cal ventricle at the septum, lateral, and inferior walls in the apical views. Peak TDI and 
SRI were measured in systole (S) and early (E) diastole. 
Results: Using TDI, differences in systolic function were only apparent between the CHF 
and the other 2 groups, but TDI could not distinguish the controls from "no-CHF". In con- 
treat, peak SRI-S distinguished "no-CHF" from controls. The difference was most appar- 
ent at the mid-ventricle (table), whereas basal peak SRI-S did not differ between "no- 
CHF" and controls. Similarly, peak SRI-E in the "no-CHF" showed a significantly lower 
value than in the controls at the mid-ventdcle but not the base, whereas TDI-E did not 
show any difference between the 'no-CRF" and controls. 
Conclusion: In cardiac amyloid, systolic and diastolic myocardial dysfunction show 
regional differences. Dysfunction is seen prominently and earliest in the mid-ventricular 
walls. The abnormalities, while poorly detected by TDI, can be demonstrated by SRI. 
